Treatment Information

Back

Colon Cancer treatment details. Chemotherapy.

University General Hospital of Heraklion, Heraklion, Greece.

Survival: monthsCountry:Greece
Toxiciy Grade:5City/State/Province:Heraklion
Treatments:ChemotherapyHospital:University General Hospital of Heraklion
Drugs:Journal:Link
Date:Feb 2006

Description:

Patients: This Phase III study involved 285 patients with metastatic colorectal cancer. The patients were randomly divided into two groups. Group B had 137 patients (76 men, 61 women) with a median age of 66 years. Metastatic sites included liver and lung, and 60% of patients in both arms had two or more metastatic sites.

Treatment: Group B received the FOLFOXIRI treatment protocol, consisting of the following four chemotherapeutic agents: oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin.

Toxicity: For Group B, two patients died of febrile neutropenia during treatment. Other grade 3-4 toxicities included neutropenia, alopecia, diarrhea, nausea/vomiting, fatigue, mucositis, neurological disorders, and nausea/vomiting.

Results: The median overall survival was 19.5 months for Group A and 21.5 months for Group B; this difference was not statistically significant. Group A had 5 complete response, 44 partial responses, and 39 with stable disease. Group B had 9 complete response, 50 partial responses and 43 with stable disease. The authors concluded, "the present study failed to demonstrate any survival advantage of the FOLFOXIRI over the FOLFIRI regimen."

Correspondence: Dr. J. Souglakos




Back